Please login to the form below

Not currently logged in
Email:
Password:

cell therapies

This page shows the latest cell therapies news and features for those working in and with pharma, biotech and healthcare.

MedCity sets up advanced therapy research network

MedCity sets up advanced therapy research network

The UK’s  life sciences hub MedCity has launched an initiative to foster greater collaboration between industry and academia in cell, tissue and gene therapies. ... The government-funded Cell and Gene Therapy Catapult is currently building a £55m

Latest news

More from news
Approximately 2 fully matching, plus 96 partially matching documents found.

Latest Intelligence

  • Making Europe a leader in bioscience: boosting trust and opening minds Making Europe a leader in bioscience: boosting trust and opening minds

    New disruptive innovation is changing the way we create value in healthcare: big data, artificial intelligence, the growing role of patients, the discovery of new materials and biologics, gene, cell and ... This involves incorporating new diagnostic

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Between November 2016 and October 2017, the FDA approved 31 new therapies for more than 16 types of tumour, including the first cell-based therapies, the first tumour-agnostic drugs and ... cell-based therapies and oncolytic viruses that attack malignant

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    class gene or cell therapies by 2022. ... Cell and gene therapies undoubtedly do pose difficult questions – but there is also no question of holding back because of this business model uncertainty.

  • No incentive for a cure No incentive for a cure

    Cell and gene therapies in particular are heralding remarkable curative medicines, which are given only once, or over the short term. ... Healthcare systems are currently set up to cover moderate costs for chronic therapies over a medium to longer period

  • The good, the bad and the ugly The good, the bad and the ugly

    The oncology market is certainly evolving. “Some of the most interesting play is in immuno-oncology, where combination therapies are increasingly being explored. ... It will also be interesting to see how gene therapies and cell-based therapies, like

More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics